Full Title: Antiageing and Life Enhancement Pharmacotherapeutics: Rejuvenating Drug Markets to 2012 and Beyond Executive Summary Facets of normal chronological ageing and lifestyle contribute to a diverse group of highly prevalent conditions that are associated with physiological or psychological deficits or symptoms of sufficient severity which compel an individual to seek medical attention to restore, alter, or improve undesired aspects of body image, physical function, or wellbeing. The conditions are wide-ranging and comprise the four major medical specialty areas of dermatology, psychiatry, reproductive health and sexual disorders, which collectively include 10 major therapy areas, some of which are alopecia, cutaneous ageing, depressive illnesses, addictions, contraception, infertility, and erectile dysfunction.
Antiageing and life enhancement therapy areas are poised for dramatic expansion over the next decade driven by factors such as increasing worldwide ageing populations, unrelenting media fixation on physical improvement and restorative antiageing treatments, and innovation in the pharmaceutical industry to bring to market highly sophisticated efficacious drug treatments that serve to close the gap between medical and cosmetic interventions. Research and development investment in the specialty area is unfaltering with over 180 companies collectively investing more than US$5 billion in the hope to capitalize on a dynamic pipeline of 275 drug candidates that are currently progressing through to the clinic. Although the capital risks are high in the antiageing and life enhacement R&D arena, the potential returns on investment are vast in a market currently estimated at US$36 billion and predicted to rise to US$49 billion by 2012, and over US$100 billion by 2020.
New drug indications combined with next generation molecules and compounds will transform the landscape of how physicians treat disorders associated with ageing or lifestyle. Current drugs are being developed with multiple therapeutic benefits that will be able to treat several ailments through single dosing. Drugs on the horizon indicated for obesity, for example, also display secondary benefits for patients with coexisting diabetes and dyslipidaemia in addition to crossover indications for tobacco addiction. In this instance the interrelation of metabolic diseases can be improved by one drug alone as opposed to three potential drug medications, a facet that will revolutionize drug treatment regimens for patients, particularly those with high cardiovascular disease risk profiles where coexisting obesity, diabetes and smoking increase disease susceptibility. Moreover, novel drugs that alter body composition or effect changes in functional aspects of daily living are anticipated to not only change the armamentarium of medical treatments in the antiageing domain but also alter the medical perceptions of antiageing and life-enhancement treatments. Novel pharmacotherapeutics may redefine treatment paradigms allowing physicians the capacity to impede or rejuvenate internal physiological ageing mechanisms or halt deleterious effects caused by lifestyle activities. Pharmacological innovation in the field may even prove beneficial in the prevention of illnesses associated with traditional drug development areas, such as in musculoskeletal disease, cancer and neurodegenerative diseases due to therapeutic synergies and shared drug targets that underly salient pathophysiological mechanisms. In short, the antiageing and life enhancement specialty area is evolving into an exciting, innovative and highly dynamic discipline.
Based on current trends, it is expected that the therapy areas will flourish offering a myriad of new drug treatment options for a range of conditions that are currently poorly served with high unmet needs.
In this report entitled Antiageing and Life Enhancement Pharmacotherapeutics: Rejuvenating Drug Markets to 2012 and Beyond, the reader will be introduced to a specialty pharmaceutical market that is transitioning to a high-growth, high-value prospect. The scope of the report encompasses up-to-date coverage of epidemiological, aetiological, and demographic data related to ageing and lifestyle disorders. Furthermore, market insights are provided by way of extensive sector analyses of marketed and newly launched products, pipeline drugs, and company activities, in addition to comment on strategic and commercial issues that may affect product positioning and revenue optimization. The report also discusses key prospects that have the potential to create new market sectors and become blockbuster products over the next decade. Pages: 580 Table of Contents Download TOC in PDF
|
